Scarica l'app Stockscreener
8.25
0.86%
0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Altimmune Inc Borsa (ALT) Ultime notizie
Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds - MSN
Altimmune (ALT) Gains on Nasdaq Biotechnology Index Inclusion - GuruFocus.com
Why Altimmune Was Such a Robustly Healthy Stock on Thursday - MSN
Altimmune (NASDAQ:ALT) Trading 4.7% HigherTime to Buy? - MarketBeat
Altimmune joins Nasdaq Biotechnology Index - Investing.com
Altimmune Joins Nasdaq Biotechnology Index, Gears Up for Pivotal MASH Drug Trial Data in 2025 - StockTitan
(ALT) Trading Report - Stock Traders Daily
Altimmune (NASDAQ:ALT) Stock Price Down 5.1%Should You Sell? - MarketBeat
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity stock outlook - Investing.com
Biodefense Market CAGR of 7.3% Size, Growth Drivers and Forecast 2024-2031 | XOMA corporation, Altimmune Inc., - EIN News
Altimmune 2025: Redefining Obesity And MASH Treatment (NASDAQ:ALT) - Seeking Alpha
Virtu Financial LLC Makes New $674,000 Investment in Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Shares Up 4.9%Still a Buy? - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Altimmune reports positive trial results for liver disease drug By Investing.com - Investing.com Nigeria
Altimmune reports positive trial results for liver disease drug - Investing.com India
Trend Tracker for (ALT) - Stock Traders Daily
Altimmune Stock Up More Than 25% in a Month: Here's Why - MSN
Portolan Capital Management LLC Sells 579,266 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity and NASH stock outlook By Investing.com - Investing.com South Africa
Altimmune's SWOT analysis: pemvidutide's potential reshapes obesity and NASH stock outlook - Investing.com Canada
Looking At Altimmune's Recent Unusual Options Activity - Benzinga
Altimmune shares surge on CEO's CNBC appearance By Investing.com - Investing.com Canada
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On WednesdayAltimmune (NASDAQ:ALT), Bitdeer Technologies (NASDAQ:BTDR) - Benzinga
Altimmune CEO on what’s next for its experimental obesity drug - CNBC
Altimmune Stock Up More Than 25% In A Month: Here's Why - Barchart
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders - The Manila Times
Altimmune CMO to Present Key Obesity Drug Data at Major Medical Conference - StockTitan
Altimmune, Inc. (NASDAQ:ALT) Stake Lifted by Bellevue Group AG - MarketBeat
How To Trade (ALT) - Stock Traders Daily
Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times
Altimmune to Present at Evercore and Piper Sandler Healthcare Conferences in December | ALT Stock News - StockTitan
Altimmune (ALT) Price Target Increased by 16.42% to 22.73 - MSN
Do Redditors Think That Altimmune Inc. (ALT) Has a Big Upside Potential? - Insider Monkey
11 Reddit Stocks with Biggest Upside Potential - Insider Monkey
FY2024 EPS Estimates for Altimmune Reduced by HC Wainwright - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Consensus Target Price from Analysts - MarketBeat
Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 - Marketscreener.com
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - The Manila Times
What is B. Riley's Forecast for Altimmune FY2024 Earnings? - MarketBeat
Altimmune's Pemvidutide Shows 68.5% Liver Fat Reduction in Phase 1b Trial Results - StockTitan
AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc - GuruFocus.com
B. Riley Weighs in on Altimmune's Q1 Earnings (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Given Buy Rating at HC Wainwright - MarketBeat
Altimmune Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):